Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer

Condition

Cancer

Respiratory

1 June 2026

Published on 31 Aug 2022
Last Updated on 01 Jun 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Tepotinib 225 mg tablet

for treating metastatic mesenchymal epithelial transition exon 14 skipping (METex14sk) mutation-positive non-small-cell lung cancer (NSCLC) in line with specific clinical criteria.

Funding status

Tepotinib 225 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) the abovementioned indication from 1 September 2022.       

MAF assistance does not apply to any formulations or strengths of capmatinib for treating metastatic METex14sk mutation-positive NSCLC

Clinical indications, subsidy class and MediShield Life claims eligibility for all drugs included in the evaluation are provided in the Annex.

Tyrosine kinase inhibitors for MET mutation-positive metastatic NSCLC (1 Jun 26) [PDF, 133 KB]

Treatments for MET exon 14 skipping mutated metastatic NSCLC PES (31 Aug 22) [PDF, 83 KB]

Back to top